"GLP-1 Friendly": A Marketing Trend... or a Regulatory Risk?
The recent article published by El País, El Comidista highlights a growing trend in the food industry: products marketed as "GLP-1 Friendly." As consumer demand increases among users of GLP-1 medications such as Ozempic®, Wegovy®, and Mounjaro®, more brands are incorporating this claim into their packaging and marketing materials. But an important regulatory question arises: Would this claim comply with U.S. FDA labeling requirements if it appears on the Principal Display Panel (PDP)? From a regulatory perspective, the answer is not straightforward . Currently, the U.S. Food and Drug Administration (FDA) has not established or authorized "GLP-1 Friendly" as a recognized nutrient content claim or health claim . Unlike claims such as "High Protein," "Good Source of Fiber," or "Low Sodium," the expression "GLP-1 Friendly" is not defined in FDA food labeling regulations. The concern goes beyond the wording itself. Today's ...
